Novaspira Biotherapeutics Press Releases - EIN Presswire

Published on November 7, 2026 - 21:00 GMT

Novaspira Biotherapeutics Reports Phase 1 Data for a Novel GPC3x4-1BB Bispecific in Late-Breaking Oral at SITC 2026

First-in-human Phase 1 results for BOS-342 (NS-342), a novel GPC3×4-1BB bispecific, demonstrate a manageable safety profile and durable antitumor activity. CHATHAM, NJ, UNITED STATES, November 7, 2026 /⁨EINPresswire.com⁩/ -- Chatham, NJ, November 7, 2026 …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on October 29, 2026 - 17:59 GMT

Novaspira Biotherapeutics Late-Breaking Oral Presentation of Phase 1 Data for a Novel GPC3x4-1BB Bispecific at SITC 2026

Novaspira Biotherapeutics Announces Late-Breaking Oral Presentation of First-in-Human Data for BOS-342 (NS-342), a Novel GPC3 × 4-1BB Bispecific at SITC 2026 CHATHAM, NJ, UNITED STATES, October 29, 2026 /⁨EINPresswire.com⁩/ -- NovaSpira Biotherapeutics …

Distribution channels: ...

Published on October 12, 2026 - 12:00 GMT

NovaSpira Announces FDA Acceptance of IND for NS - 342 in GPC3 Positive Tumors

NovaSpira Biotherapeutics Secures U.S. FDA Acceptance of IND Application for NS 342 in Advanced Hepatocellular Carcinoma and Other GPC3 Expressing Solid Tumors CHATHAM, NJ, UNITED STATES, October 12, 2026 /⁨EINPresswire.com⁩/ -- NovaSpira Biotherapeutics …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on August 31, 2026 - 12:00 GMT

NovaSpira Receives MFDS Approval to Start Phase 1 Trial of NS 342 (GPC3x4-1BB Bispecific) in Advanced Solid Tumors

CHATHAM, NJ, UNITED STATES, August 31, 2026 /⁨EINPresswire.com⁩/ -- NovaSpira Biotherapeutics today announced that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has approved the company’s updated Phase 1 clinical trial plan for NS‑ …

Distribution channels: Healthcare & Pharmaceuticals Industry ...